Blog
RSS FeedPosted by Michael Wonder on 05 Feb 2024
Selinexor in combination with bortezomib and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma
2 February 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 04 Feb 2024
Ruxolitinib phosphate for the treatment of patients with non-segmental vitiligo
31 January 2024 - The Department of Health and Social Care has asked NICE to produce guidance on using ruxolitinib ...
Posted by Michael Wonder on 02 Feb 2024
Fenfluramine hydrochloride for the treatment of patients with Lennox-Gastaut seizures
31 January 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 01 Feb 2024
Ivosidenib for the treatment of patients with advanced IDH1 R132 mutation positive cholangiocarcinoma after one or more systemic treatments
31 January 2024 - NICE has published final evidence-based recommendations on the use of ivosidenib (Tibsovo) for the treatment of ...
Posted by Michael Wonder on 31 Jan 2024
Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments
31 January 2024 - NICE has published evidence-based recommendations on the use of loncastuximab tesirine (Zynlonta) for the treatment of ...
Posted by Michael Wonder on 30 Jan 2024
Treosulphan in combination with fludarabine phosphate before allogeneic stem cell transplantation for patients aged 1 month to 17 years with non-malignant diseases
30 January 2024 - NICE is unable to make a recommendation on the use of treosulphan (Trecondi) in combination with fludarabine ...
Posted by Michael Wonder on 23 Jan 2024
Remdesivir and the combination of tixagevimab and cilgavimab for the treatment of patients with COVID-19 disease
18 January 2024 - NICE has published additional draft guidance on the use of remdesivir and the combination of tixagevimab ...
Posted by Michael Wonder on 19 Jan 2024
300 people to benefit from new treatment for advanced breast cancer recommended by NICE following price deal
19 January 2024 - Around 300 people are set to benefit following NICE’s recommendation of talazoparib tosylate for treating a type ...
Posted by Michael Wonder on 17 Jan 2024
Olaparib in combination with bevacizumab for the maintenance treatment of adults with advanced high grade epithelial ovarian, fallopian tube or primary peritoneal cancer
17 January 2024 - NICE has published evidence-based recommendations on the use of olaparib (Lynparza) in combination with bevacizumab (Avastin) ...
Posted by Michael Wonder on 15 Jan 2024
Sebelipase alfa for the treatment of patients with Wolman disease (final guidance)
10 January 2023 - Sebelipase alfa is recommended as an option for the treatment of patients with Wolman disease only if ...
Posted by Michael Wonder on 21 Dec 2023
Ravulizumab for the treatment of patients with AQP4 antibody positive neuromyelitis optica spectrum disorder
20 December 2023 - NICE is unable to make a recommendation on the use of ravulizumab (Ultomiris) for the treatment of ...
Posted by Michael Wonder on 20 Dec 2023
Empagliflozin for the treatment of patients with chronic kidney disease
20 December 2023 - NICE has published evidence-based recommendations on the use of empagliflozin (Jardiance) for the treatment of adults ...
Posted by Michael Wonder on 20 Dec 2023
Budesonide for the treating primary IgA nephropathy
20 December 2023 - NICE has published evidence-based recommendations on the use of budesonide (Kinpeygo) for the treatment of adults ...
Posted by Michael Wonder on 20 Dec 2023
Ravulizumab for the treatment of patients with generalised myasthenia gravis
20 December 2023 - NICE is unable to make a recommendation on the use of ravulizumab (Ultomiris) for the treatment of ...
Posted by Michael Wonder on 13 Dec 2023
Velmanase alfa for the treatment of patients with alfa mannosidosis
13 December 2023 - NICE has published final evidence-based recommendations on the use of velmanase alfa (Lamzede) for treatment of ...